Indaba Capital Management’s Standard BioTools LAB Stock Holding History

Indaba Capital Management’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-7,363,064	Closed	-$20M	–	9
2024 Q1	$20M	Sell	7,363,064 -83,165	-1%	-$201K	13.03%	5
2023 Q4	$16.5M	Hold	7,446,229	–	–	9.45%	5
2023 Q3	$21.6M	Hold	7,446,229	–	–	6.36%	7
2023 Q2	$14.4M	Hold	7,446,229	–	–	4.86%	7
2023 Q1	$14.5M	Hold	7,446,229	–	–	4.49%	9
2022 Q4	$8.71M	Hold	7,446,229	–	–	1.69%	19
2022 Q3	$8.19M	Hold	7,446,229	–	–	1.26%	23
2022 Q2	$11.9M	Hold	7,446,229	–	–	1.57%	23
2022 Q1	$26.7M	Hold	7,446,229	–	–	3.03%	14
2021 Q4	$29.2M	Hold	7,446,229	–	–	3.13%	15
2021 Q3	$49.1M	Hold	7,446,229	–	–	5.2%	5
2021 Q2	$45.9M	Hold	7,446,229	–	–	4.95%	7
2021 Q1	$33.7M	Buy	7,446,229 +1,915,629	+35%	+$10.5M	4.23%	8
2020 Q4	$33.2M	Buy	5,530,600 +1,566,848	+40%	+$10.3M	5.85%	8
2020 Q3	$29.5M	Hold	3,963,752	–	–	9.36%	4
2020 Q2	$15.9M	Buy	3,963,752 +143,786	+4%	+$501K	6.02%	7
2020 Q1	$9.7M	Buy	3,819,966 +496,978	+15%	+$1.63M	5.23%	9
2019 Q4	$11.6M	Buy	3,322,988 +601,700	+22%	+$2.12M	4.68%	8
2019 Q3	$12.6M	Buy	+2,721,288	New	+$21.4M	2.95%	14
2019 Q1	–	Sell	-400,000	Closed	-$3.45M	–	25
2018 Q4	$3.45M	Buy	+400,000	New	+$3.12M	0.76%	24

Other funds holding LAB

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Tikvah Management Charlotte, North Carolina $323M AUM 69.61% 1-Year Est. Return

Indaba Capital Management's LAB Position: Q2 2024 in Review

Indaba Capital Management sold out of Standard BioTools (LAB) in Q2 2024, closing a stake of 7,363,064 shares — an estimated $20M sold.

Indaba Capital Management first reported a position in LAB in Q4 2018 and held it in 20 quarters. The position peaked at $49.1M in Q3 2021. 144 funds tracked by Wall St. Rank hold LAB as of Q2 2024.

Indaba Capital Management reported no remaining Standard BioTools position as of Q2 2024 after selling out during the quarter.
Indaba Capital Management sold 7,363,064 Standard BioTools shares in Q2 2024, an estimated $20M.
Indaba Capital Management first reported a position in Standard BioTools in Q4 2018 and held it in 20 quarters.
Indaba Capital Management's Standard BioTools position peaked at $49.1M in Q3 2021.
144 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2024.

Based on Indaba Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.